Observational studyThe breast journal2025
Predictive Value of Pyroptosis Markers (NLRP3, HMGB1, and Caspase-1) in the Prognosis of Patients With Metastatic Breast Cancer: A Prospective Observational Study.
Observational study in The breast journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The predictive value of serum pyroptosis markers, including NOD-like receptor family pyrin domain containing 3 (NLRP3), high mobility group box 1 (HMGB1), and caspase-1, in metastatic breast cancer (MBC) patients was investigated. Methods: A prospective observational study was conducted, enrolling MBC patients who had not undergone prior radiotherapy or chemotherapy. Serum levels of pyroptosis markers (NLRP3, HMGB1, and caspase-1) and conventional tumor markers, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and cancer antigen 15-3 (CA15-3), were measured using enzyme-linked immunosorbent assay (ELISA) kits. Demographic and clinical data were collected, including age, tumor size, hormone receptor status, and metastatic sites. Patients were followed up for 24 months, and overall survival (OS) was recorded. Results: The study included 122 MBC patients, categorized into the favorable and poor prognosis groups based on 24-month survival. Elevated levels of NLRP3 and HMGB1 were significantly associated with poor prognosis, whereas lower levels of caspase-1 were observed in patients with unfavorable outcomes. Receiver operating characteristic (ROC) curve analysis demonstrated that pyroptosis markers, particularly caspase-1, had significant predictive value for MBC prognosis. Kaplan-Meier curves showed that patients with high HMGB1 levels had a shorter 24-month OS, whereas those with low caspase-1 levels also exhibited a shorter 24-month OS. Multivariate logistic regression analysis identified tumor diameter, Ki67, molecular subtype, number of metastatic sites per patient, and HMGB1 were independent risk factors for poor prognosis in MBC patients, whereas caspase-1 was an independent protective factor against poor prognosis. Conclusion: Serum pyroptosis markers (HMGB1 and caspase-1) were valuable prognostic indicators in MBC patients. Elevated HMGB1 levels, along with reduced caspase-1 levels, were associated with poorer outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.